Literature DB >> 28834123

Pregnancy outcomes in women with Budd Chiari Syndrome before onset of symptoms and after treatment.

Akash Shukla1, Abhishek Sadalage1, Deepak Gupta1, Amit Gupte1, Anupam Mahapatra1, Dipendu Mazumder1, Chirag Shah1, Tejas Modi1, Megha Meshram1, Prashant Dhore1, Shobna Bhatia1.   

Abstract

BACKGROUND & AIMS: Pregnancy is known to have poor outcomes in women with Budd Chiari syndrome. There are no data on fertility and pregnancy outcomes prior to onset of symptoms or the effect of therapy on these parameters. We therefore evaluated reproductive profile of women with Budd Chiari Syndrome before the onset of symptoms and after therapy. PATIENTS AND METHODS: Eighty women with Budd Chiari Syndrome (29 years [20-45]) were enrolled over 8 years. Baseline demographic characteristics, disease severity, thrombophilic disorders and treatment were reviewed. Their obstetric history before symptoms and after therapy was noted and compared.
RESULTS: Sixty women conceived at least once (150 pregnancies) before symptom onset and 20 had primary infertility. Eighty-one pregnancies resulted in live births and remaining 69 pregnancies had adverse pregnancy outcomes. Post-intervention, 28 women (15 with primary infertility) attempted conception. Thirteen patients conceived 15 times. More women had live births after successful therapy as compared to presymptomatic period (0/28 vs 5/28 P = .000, Odds ratio5.6; 95% CI: 2.16-14.5). In women with primary infertility, conception (0/15 vs 3/15 P = .007, Odds ratio 5, 95% CI: 1.44-17.27) and proportion of live births (0/15 vs 2/15 P = .002, Odds ratio 7.5, 95% CI: 1.71-32.79) was higher as compared to presymptomatic period.
CONCLUSION: Primary infertility is common and pregnancy outcomes are poor before the onset of symptoms in women with Budd-Chiari syndrome. Effective therapy of Budd-Chiari syndrome may improve fertility and pregnancy outcomes.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  conception; fetal outcomes; infertility; quality of life

Mesh:

Substances:

Year:  2017        PMID: 28834123     DOI: 10.1111/liv.13552

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  4 in total

1.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

Review 2.  Indian National Association for the Study of the Liver-Federation of Obstetric and Gynaecological Societies of India Position Statement on Management of Liver Diseases in Pregnancy.

Authors:  Anil Arora; Ashish Kumar; Anil C Anand; Pankaj Puri; Radha K Dhiman; Subrat K Acharya; Kiran Aggarwal; Neelam Aggarwal; Rakesh Aggarwal; Yogesh K Chawla; Vinod K Dixit; Ajay Duseja; Chundamannil E Eapen; Bhabadev Goswami; Kanwal Gujral; Anoop Gupta; Ankur Jindal; Premashish Kar; Krishna Kumari; Kaushal Madan; Jaideep Malhotra; Narendra Malhotra; Gaurav Pandey; Uma Pandey; Ratna D Puri; Ramesh R Rai; Padaki N Rao; Shiv K Sarin; Aparna Sharma; Praveen Sharma; Koticherry T Shenoy; Karam R Singh; Shivaram P Singh; Vanita Suri; Nirupama Trehanpati; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2019-03-06

Review 3.  State of the Art, Current Perspectives, and Controversies of Budd-Chiari Syndrome: A Review.

Authors:  Paschalis Gavriilidis; Gabriele Marangoni; Jawad Ahmad; Daniel Azoulay
Journal:  J Clin Med Res       Date:  2022-04-30

4.  Pregnancy outcomes in women with Budd-Chiari syndrome or portal vein thrombosis - a multicentre retrospective cohort study.

Authors:  Hmg Wiegers; E N Hamulyák; S E Damhuis; J R van Duuren; S Darwish Murad; Ljj Scheres; S J Gordijn; J Leentjens; J J Duvekot; M N Lauw; B A Hutten; S Middeldorp; W Ganzevoort
Journal:  BJOG       Date:  2021-10-04       Impact factor: 7.331

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.